
Cellectis Investor Relations Material
Latest events

Q4 2024
Cellectis
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Cellectis S.A.
Access all reports
Cellectis is a clinical stage biotechnological company, developing immuno-oncology products based on gene-edited T-cells. According to Cellectis, it is one of the very few companies capable of generating next generation T-cell product candidates in an entirely novel approach. By combining the full functionality of T-cells with the specificity provided by artificial antigen receptors (chimeric antigen receptors), their program aims at achieving superior antiviral, anti-tumor and anti-inflammatory potential.
Latest articles
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
)
500 Years of Craft, One Family Legacy: Beretta Holding's Global Expansion
How Beretta Holding managed to transform from a 16th-century gun barrel producer into a global industrial group while preserving 500 years of legacy.
27 Jun 2025
)
Shuntaro Furukawa: The Sixth President of Nintendo
Shuntaro Furukawa, Nintendo's sixth president, went from a childhood fan to leading the company through global expansion and the launch of Switch 2.
23 Jun 2025
Ticker symbol
ALCLS
Country
🇫🇷 France